ATR and cancer: Extended from the study, ARID1A‐deficient cancer cells were found to be susceptible to Ataxia‐telangiectasia and rad3‐related protein kinase (ATR) inhibitors because these cancer cells show defects in topoisomerase 2A and cell cycle regulation, leading to a dependency in ATR function.24